key: cord-0430449-y9i7fv1z authors: Gong, Shang Yu; Chatterjee, Debashree; Richard, Jonathan; Prévost, Jérémie; Tauzin, Alexandra; Gasser, Romain; Bo, Yuxia; Vézina, Dani; Goyette, Guillaume; Gendron-Lepage, Gabrielle; Medjahed, Halima; Roger, Michel; Côté, Marceline; Finzi, Andrés title: Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity date: 2021-08-04 journal: bioRxiv DOI: 10.1101/2021.08.04.455140 sha: 1e5c841489c698f9aee199a93e40c6407072ac91 doc_id: 430449 cord_uid: y9i7fv1z Towards the end of 2020, multiple variants of concern (VOCs) and variants of interest (VOIs) have arisen from the original SARS-CoV-2 Wuhan-Hu-1 strain. Mutations in the Spike protein are highly scrutinized for their impact on transmissibility, pathogenesis and vaccine efficacy. Here, we contribute to the growing body of literature on emerging variants by evaluating the impact of single mutations on the overall antigenicity of selected variants and their binding to the ACE2 receptor. We observe a differential contribution of single mutants to the global variants phenotype related to ACE2 interaction and antigenicity. Using biolayer interferometry, we observe that enhanced ACE2 interaction is mostly modulated by a decrease in off-rate. Finally, we made the interesting observation that the Spikes from tested emerging variants bind better to ACE2 at 37°C compared to the D614G variant. Whether improved ACE2 binding at higher temperature facilitates emerging variants transmission remain to be demonstrated. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of 43 COVID-19, remains an major public health concern, infecting over 185 million individuals and 44 causing over 4 million deaths worldwide (Dong et al., 2020) . The replication cycle of SARS-CoV-45 2 starts with viral attachment to the target cell and fusion between viral and cellular membranes. 46 The viral entry process is mediated by the mature Spike (S) glycoprotein trimer which is composed 47 stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded on 135 SDS-PAGE gels and stained with Coomassie Blue. Baseline equilibration was collected for 120 s in 10X kinetics buffer. Association of sACE2 (in 175 10X kinetics buffer) to the different RBD proteins was carried out for 180 s at various 176 concentrations in a two-fold dilution series from 500nM to 31.25nM prior to dissociation for 300 177 s. The data were baseline subtracted prior to fitting performed using a 1:1 binding model and the 178 FortéBio data analysis software. Calculation of on-rates (Ka), off-rates (Kdis), and affinity constants 179 (KD) was computed using a global fit applied to all data. 183 Since the SARS-CoV-2 Spike is under strong selective pressure and is responsible for 184 interacting with the ACE2 receptor, we measured the ability of the Spike from emerging variants 185 to interact with ACE2 and the contribution of each single mutations toward this binding. 195 presented significantly higher ACE2 binding ( Fig 1A) . 196 We then determine the contribution of individual Spike mutations on ACE2 binding to 197 discern the ones contributing to the heightened receptor affinity of emerging variants. The B.1.1.7 Spike presented the highest ACE2-Fc interaction amongst all tested Spikes, which is a 5.43-fold 199 increase in ACE2-Fc binding compared to D614G (Fig 1A-B and Table S2 ). The mutations that 200 likely contribute to this phenotype are ΔH69-V70 in the N terminal domain (NTD) and N501Y in 201 the RBD that enhanced binding by ~1.51 and ~2.52 folds, respectively (Fig 1B) . The Spike from B.1.351 also presented significantly higher ACE2-Fc binding compared to 203 D614G. Similarly to B.1.1.7, the N501Y mutation likely plays an important role in this phenotype 204 (Fig. 1C) . Interestingly, three mutations/deletion in this VOC decreased the interaction with 205 ACE2-Fc, namely R246I and Δ242-244 in the NTD, as well as K417N in the RBD. The NTD 206 substitution R246I decreased ACE2-Fc binding by ~1.52 folds , the Δ242-244 deletion by ~1.35 207 folds, whereas K417N had a greater impact with a decreased binding of ~7.7 folds relative to 208 D614G ( Fig 1C) . Of note, the E484K mutation, also found in the RBD of other emerging variants 209 (P.1 and B.1.526) did not significantly impact the ACE2-Fc interaction. The Spike from P.1 presented a ~4.24-fold increase in binding compared to D614G (Fig 211 1D ). Few NTD mutations, namely T20N, P26S, D138Y, and R190S, likely contributed to the 212 increase in ACE2 binding, with ~2, ~1.6, ~1.3 and ~1.8-fold increase compared to D614G, 213 respectively. Like the above-mentioned VOCs, N501Y also likely played a role in enhanced 214 ACE2-Fc interaction. Interestingly, the RBD mutation K417T and the S2 mutation T1027I 215 decreased the ACE2-Fc by ~1.3 and ~1.7 folds respectively. The H655Y mutation, near the S1/S2 216 cleavage site, also slightly increased ACE2 interaction by ~1.2 folds (Fig 1D) . The Spike from B.1.429 augmented ACE2-Fc interaction by ~2.8 folds ( Fig 1E) . This VOI 218 has two NTD mutations, S13I and W152C, both of which did not significantly impact this 219 interaction. On the other hand, its RBD mutation, L452R, increased ACE2-Fc binding by ~2.7 220 folds, suggesting its major contribution to the phenotype of this variant ( Fig 1E) . Lastly, the Spike from B.1.526 showed a ~1.8-fold increase over D614G (Fig 1F) . None of the mutation appears to explain the phenotype observed with the full variant. While our results identified some key mutations enhancing ACE2 interaction (i.e., 224 N501Y,L452R and mutation/deletion in the NTD), the overall increased ACE2 affinity from any 225 given variant appears to result from more than the sum of the effect of individual mutations 226 composing this variant. Impact of selected mutations on the affinity of Spike RBD for ACE2 229 Next, we used biolayer interferometry (BLI) to measure the binding kinetics of selected 230 RBD mutants to soluble ACE2 (sACE2). Biosensors were coated with recombinant RBD and put 231 in contact with increasing concentration of sACE2 (Fig 2) . In agreement with previous reports 232 (Prévost et al., 2021; Zhu et al., 2021) , the N501Y mutation present in B.1.1.7, B.1.351, and P.1 233 significantly decreased the off-rate (Kdis) (from 6.88×10 -3 to 1.49×10 -3 1/s), presenting a 3.88-fold 234 increase in KD compared to its wild-type counterpart (Fig 2A-B , Table S1 ). Substitution at position Table S1 ). Although both K417N 237 and K417T presented a modest increase in the on-rate kinetic by ~1.56 and ~ 1.11 folds, the 238 accelerated off-rate kinetics dictated the overall decrease affinity of these mutants. No major 239 changes were observed for the E484K mutation ( Fig 2F) . Interestingly, the L452R mutant did not harboring the N501Y mutation present better ACE2 binding at higher temperatures compared to 250 the D614G strain (Prévost et al., 2021) . To evaluate whether the Spikes from the emerging variants 251 tested here also shared this phenotype, Spike-expressing cells were incubated at either 4ºC or 37ºC, 252 and their ACE2-Fc binding was measured by flow cytometry. As presented in Fig. 3 Spike are the ΔY144 deletion in the NTD, P681H and T716I near the S1/S2 cleavage site (Fig 4B) . The N501Y substitution, also present in other emerging variants (B1.351 and P.1), is the only 278 mutation that increased plasma recognition. Polyclonal recognition of the P.1 Spike was reduced by ~1.33 folds ( Fig 4D) . Our results show that all the NTD mutations, namely L18F, T20N, P26S, D138Y and R190S, attenuated the 286 binding of naïve-vaccinated plasma Abs ( Fig 4D) . Furthermore, H655Y also contributed to the 287 immuno-evasive phenotype of the full Spike ( Fig 4D) . Again, N501Y is the only mutation that 288 increased plasma recognition, indicating its major role amongst all the mutations of this variant. Although the full B.1.429 Spike did not show a significant evasion of plasma recognition, 291 all of its mutations presented a significant decrease in plasma binding ( Fig 4E) . Both its NTD 292 mutations, S13I and W152C, were less efficiently recognized by plasma compared to D614G (Fig 293 4E ). The RBD mutation L452R also presented a minor ~1.16-fold decrease in recognition by 294 plasma from vaccinated individuals. Lastly, the B.1.526 full Spike variant did not significantly 295 affect vaccine-elicited plasma recognition. The same phenotype is applicable to most of its 296 mutations, with the exception of D253G substitution in the NTD, which showed a modest ~1.2-297 fold decrease in binding ( Fig 4F) . 298 We then evaluated the recognition of our panel of Spikes (VOC, VOI and single mutants) 299 by plasma from previously-infected vaccinated individuals (plasma recovered three weeks post While the D614G Spike necessitates lower temperature for optimal ACE2 interaction, Spikes from 354 the different VOCs and VOIs seem to bypass this requirement to efficiently interact with ACE2 at 355 higher temperature (37 ºC). However, whether improved ACE2 binding at higher temperature temperatures. 365 We also found that plasma from vaccinated SARS-CoV-2 naïve and prior-infected The authors declare that they have no known competing financial interests or personal 423 relationships that could have appeared to influence the work reported in this paper. Table S1 . significance has been performed using Mann-Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001; 797 ****p < 0.0001). Previously-infected vaccinated ** ** ** ** ** ** ** ** ** Table S1 : Binding Kinetics of the interaction between SARS-CoV-2 RBD and sACE2 quantified by Biolayer Interferometry. Plasma binding were normalized to CV3-25 in each experiment. Values are presented as ratio of normalized plasma binding obtained with the D614G Spike. Values represent the means of data obtained with 3-5 plasma from the same group. c) The ID50 represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by recombinant viruses bearing the indicated Spike. Values are presented as the means of ID50 and as ratio of the ID50 obtained with virus bearing the D614G Spike. Values represent the means of data obtained with 3-5 different plasma. Safety 676 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 677 four randomised controlled trials in Brazil, South Africa, and the UK Structure, Function, 679 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Unexpected Receptor 682 Functional Mimicry Elucidates Activation of Coronavirus Fusion Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 686 694 Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States 699 Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. bioRxiv Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Cryo-electron microscopy 706 structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing 707 antibodies Statistical analyses were used to compare each Spike at 4ºC vs 37ºC (black) or to 737 compare variants Spike to D614G at 37ºC (red) or at 4ºC (blue). Fold changes of ACE2 binding at 738 4ºC vs 37ºC for each Spike is shown in black 0001, ns; non-significant) Recognition of SARS-CoV-2 Spike variants and single mutants by plasma from 743 vaccinated SARS-CoV-2 naïve individuals Two days post 745 transfection, cells were stained with 1:250 dilution of plasma collected from naive post vaccinated 746 individuals (n=3-5) or with CV3-25 Ab as control and analyzed by flow cytometry Spike and variant-specific Spike single mutations are presented as ratio of plasma binding to 749 D614G Spike normalized CV3-25 binding. Error bars indicate means± SEM. Statistical 750 significance has been performed using Mann-Whitney U test Recognition of SARS-CoV-2 Spike variants and single mutants by plasma from 754 vaccinated previously-infected individuals HEK293T cells were transfected with SARS-CoV-2 full Spike variants and stained with plasma 756 collected 3 weeks post-first dose vaccinated previously infected individuals (n=3-5) or with Ab and analyzed by flow cytometry. Plasma recognition of (A) full Spike variants or the (B) 758 (E) B.1.429, (F) B.1.526 Spikes and Spikes with their corresponding 759 single mutations are presented as a ratio of plasma binding to D614G Spike normalized with CV3-760 25 binding Figure 6. Neutralization of SARS-CoV-2 Spike variants by plasma from previously infected Neutralizing activity of previously infected vaccinated individuals against pseudoviruses bearing 766 the SARS-CoV-2 Spike variants were assessed. Pseudoviruses with serial dilutions of plasma were 767 incubate for 1 h at 37°C before infecting 293T-ACE2 cells. ID50 against pseudoviruses were 768 calculated by a normalized non-linear regression using GraphPad Prism software. Detection limit 769 is indicated in the graph (ID50=50)